We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Virtual Staining Technology Paves Way for Non-Invasive Pathological Diagnosis

By LabMedica International staff writers
Posted on 27 May 2025

For more than 200 years, traditional pathology has depended on the technique of examining cancer tissues under a microscope, a method that provides only limited, specific cross-sections of the 3D structure of cancer cells. More...

This restriction has hindered the ability to fully comprehend the three-dimensional relationships and spatial organization of cells within the tumor. Researchers have now introduced an innovative virtual staining technology that offers a detailed, 3D view of cancer tissues without the need for separate staining, surpassing the conventional methods that involve observing thinly sliced and stained tissue sections.

This cutting-edge technology, developed by an international team led by the Korea Advanced Institute of Science and Technology (KAIST, Daejeon, Republic of Korea), combines advanced optical techniques with an artificial intelligence (AI)-driven deep learning algorithm to produce realistic, virtually stained 3D images of cancer tissue. The team employed holotomography (HT), an advanced optical technology, to measure the 3D refractive index of tissue samples. The AI-based deep learning algorithm was then integrated to generate virtually stained H&E images. This breakthrough is expected to revolutionize pathological diagnostics by enabling non-invasive, next-generation cancer analysis.

In their study, published in Nature Communications, the researchers quantitatively demonstrated that the images produced by this technology closely resemble actual stained tissue samples. Additionally, the technology showed reliable performance across different organs and tissue types, confirming its versatility and potential as an advanced tool for pathological analysis. Through collaborative research with hospitals and institutions in Korea and the United States, utilizing Tomocube's holotomography equipment, the team validated the feasibility of the technology and showcased its potential for widespread implementation in real-world pathological research environments.

"This research marks a major advancement by transitioning pathological analysis from conventional 2D methods to comprehensive 3D imaging,” said KAIST Professor YongKeun Park who led the research team. “It will greatly enhance biomedical research and clinical diagnostics, particularly in understanding cancer tumor boundaries and the intricate spatial arrangements of cells within tumor microenvironments."


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.